MariMed (OTCMKTS:MRMD) Lowered to “Strong Sell” Rating by Zacks Research

Zacks Research lowered shares of MariMed (OTCMKTS:MRMD) from a hold rating to a strong sell rating in a research report report published on Tuesday,Zacks.com reports.

Separately, Ventum Cap Mkts lowered MariMed from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold”.

MariMed Price Performance

MRMD stock traded up $0.00 during trading on Tuesday, reaching $0.09. The company’s stock had a trading volume of 1,070,859 shares, compared to its average volume of 838,609. The company has a quick ratio of 0.36, a current ratio of 1.06 and a debt-to-equity ratio of 1.34. MariMed has a 1 year low of $0.07 and a 1 year high of $0.23. The company’s fifty day moving average is $0.14 and its 200-day moving average is $0.11. The company has a market capitalization of $35.89 million, a P/E ratio of -2.28 and a beta of 2.96.

MariMed (OTCMKTS:MRMD) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.01) EPS for the quarter, hitting analysts’ consensus estimates of ($0.01). MariMed had a negative return on equity of 14.67% and a negative net margin of 11.36%.The company had revenue of $40.76 million for the quarter, compared to analysts’ expectations of $42.15 million.

About MariMed

MariMed Inc engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature’s Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby’s Baked brand; and drink mix under Vibations brand.